Breast cancer cells express four types of 5-HT receptors, and their binding to 5-HT induces PTHrP through RUNX2, inhibits osteoblast maturation and activates osteoclasts through the RANKL pathway [207]. This evidence concerns the gene RUNX2 and breast cancer.